» Articles » PMID: 30232818

ETFDH Mutations and Flavin Adenine Dinucleotide Homeostasis Disturbance Are Essential for Developing Riboflavin-Responsive Multiple Acyl-Coenzyme A Dehydrogenation Deficiency

Overview
Journal Ann Neurol
Specialty Neurology
Date 2018 Sep 21
PMID 30232818
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Riboflavin-responsive multiple acyl-coenzyme A dehydrogenation deficiency (RR-MADD) is an inherited fatty acid metabolism disorder mainly caused by genetic defects in electron transfer flavoprotein-ubiquinone oxidoreductase (ETF:QO). The variant ETF:QO protein folding deficiency, which can be corrected by therapeutic dosage of riboflavin supplement, has been identified in HEK-293 cells and is believed to be the molecular mechanism of this disease. To verify this hypothesis in vivo, we generated Etfdh knockin (KI) mice.

Methods: Tissues from these mice as well as muscle biopsies and fibroblasts from 7 RR-MADD patients were used to examine the flavin adenine dinucleotide (FAD) concentration and ETF:QO protein amount.

Results: All of the homozygous KI mice (Etfdh , KI/KI) were initially normal. After being given a high-fat and vitamin B -deficient (HF-B D) diet for 5 weeks, they developed weight loss, movement ability defects, lipid storage in muscle and liver, and elevated serum acyl-carnitine levels, which are clinically and biochemically similar to RR-MADD patients. Both ETF:QO protein and FAD concentrations were significantly decreased in tissues of HF-B D-KI/KI mice and in cultured fibroblasts from RR-MADD patients. After riboflavin treatment, ETF:QO protein increased in proportion to elevated FAD concentrations, but not related to mRNA levels. These results were further confirmed in cultured fibroblasts from RR-MADD patients.

Interpretation: For the first time, we successfully developed a RR-MADD mice model and confirmed that FAD homeostasis disturbances played a crucial role on the pathomechanism of RR-MADD in this mouse model and culture cells from patients. Supplementation of riboflavin may stabilize variant ETF:QO protein by rebuilding FAD homeostasis. Ann Neurol 2018;84:667-681.

Citing Articles

Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency Presenting as Hyperammonemia and Encephalopathy: Case Series.

Viguera Altolaguirre C, Stergachis A, Sweetser D, Gold N Neurohospitalist. 2025; :19418744251324959.

PMID: 40051723 PMC: 11881097. DOI: 10.1177/19418744251324959.


ETFDH mutation involves excessive apoptosis and neurite outgrowth defect via Bcl2 pathway.

Lin C, Liang W, Yu Y, Chang S, Lai M, Jong Y Sci Rep. 2024; 14(1):25374.

PMID: 39455656 PMC: 11511830. DOI: 10.1038/s41598-024-75286-4.


The male-to-female ratio in late-onset multiple acyl-CoA dehydrogenase deficiency: a systematic review and meta-analysis.

Ma J, Zhang H, Liang F, Li G, Pang X, Zhao R Orphanet J Rare Dis. 2024; 19(1):72.

PMID: 38365830 PMC: 10873946. DOI: 10.1186/s13023-024-03072-6.


Vitamin B2 enables regulation of fasting glucose availability.

Masschelin P, Saha P, Ochsner S, Cox A, Kim K, Felix J Elife. 2023; 12.

PMID: 37417957 PMC: 10328530. DOI: 10.7554/eLife.84077.


Late-onset multiple acyl-CoA dehydrogenase deficiency: an insidious presentation.

Rao N, Burns K, Manolikos C, Hodge S BMJ Case Rep. 2023; 16(5).

PMID: 37217231 PMC: 10230867. DOI: 10.1136/bcr-2022-252668.